PSEUDOMONAS AERUGINOSA INFECTION: MODERN APPROACHES TO MANAGEMENT OF THE MOST SIGNIFICANT CLINICAL FORMS OF PATHOLOGY

Introduction. At present, antimicrobial therapy of ventilator-associated pneumonia and bacteremia caused by Pseudomonas aeruginosa is an urgent problem due to the high prevalence of microbial multiresistant strains and their ability to develop resistance to new antibacterial drugs. Materials and methods. The analysis and generalization of the results of scientific studies highlighted in fundamental medical journals related to the treatment of ventilator-associated pneumonia and bacteremia caused by Pseudomonas infection are carried out. Results. The main points in the modern approach to the effective treatment of ventilator-associated pneumonia and bacteremia caused by Pseudomonas aeruginosa include the correct empirical choice of the starting antibacterial agent in accordance with the local epidemiology of the medical setting, timely beginning of the treatment, options to combine drugs with a tendency to de-escalation to monotherapy. It is also important to choose the optimal drug in terms of its pharmacological parameters and a clear definition of the optimal therapeutic dosage. The article describes the main groups of drugs currently used in the treatment of the main clinical forms of Pseudomonas aeruginosa. Nowadays, it is recommended to combine therapy for pseudomonas ventilator-associated pneumonia and bacteremia with antipseudomonas penicillins or cephalosporins or carbapenems plus fluoroquinolones or aminoglycosides or colistin with phosphomycin. Conclusions. Despite the elaboration of the modern approaches to the antimicrobial therapy of infections caused by Pseudomonas aeruginosa, this issue is still debatable and requires further study.